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Reply
We thank Dr. Raposeiras-Roubı´n and colleagues for their interest
in our paper (1). They postulate that advanced glycation endprod-
ucts (AGEs) may mediate the association between hyperglycemia
and myocardial damage. We mentioned AGEs as a possible
mechanism that may explain the observed association between
glycated hemoglobin (HbA1c) and high-sensitivity cardiac tro-
onin T (hs-cTnT) in our study. We agree that this is an
nteresting question that deserves further study. Unfortunately, it is
ifficult to obtain tissue AGE measurements in population-based
tudies and, unlike HbA1c, blood AGEmeasurements are not used
clinically.Dr. Farmakis and colleagues express concern that we excluded
participants with a history of coronary heart disease, stroke,
chronic kidney disease, or atrial fibrillation in our study of a
community-based population. These exclusions are important
because hs-cTnT will be elevated in the setting of structural heart
disease and circulating levels may be affected by kidney function.
Stronger associations between HbA1c and hs-cTnT were observed
n the overall study population when no exclusions were applied.
r. Farmakis and colleagues also discuss uncertainty surrounding
he interpretation of slightly elevated troponin levels in the general
opulation. We agree with both Dr. Farmakis and colleagues and
r. Korosoglou and colleagues that additional studies are needed
o understand the potential clinical relevance of new hs-cTnT
ssays.
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